FATE THERAPEUTICS INC (FATE)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, FATE THERAPEUTICS INC reported revenue of $6.65M, down 51.2% from the prior year. The company ran a net loss, with a net margin of -2051.1%.
Key ratios (FY2025)
-2222.4%
Operating margin
-2051.1%
Net margin
-65.8%
Return on equity
-51.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.65M | $13.63M | $63.53M | $96.30M | $55.85M | $31.43M | $10.68M | $4.74M | $4.11M | $4.40M |
| Operating Income | -$147.70M | -$210.28M | -$190.51M | -$308.39M | -$216.99M | -$128.09M | -$100.73M | -$67.09M | -$42.12M | -$31.96M |
| Net Income | -$136.31M | -$186.26M | -$160.93M | -$281.72M | -$212.15M | -$173.39M | -$98.15M | -$66.60M | -$42.95M | -$33.46M |
| EPS (Diluted) | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 | $-2.10 | — | — | — | — |
| Total Assets | $318.94M | $440.69M | $506.22M | $705.56M | $921.46M | $622.46M | $302.27M | $213.03M | $105.29M | $95.05M |
| Shareholders' Equity | $207.18M | $318.73M | $368.42M | $483.94M | $678.84M | $384.44M | $244.76M | $160.47M | $77.19M | $73.15M |
| Cash & Equivalents | $46.63M | $36.06M | $41.87M | $61.33M | $133.58M | $167.35M | $99.81M | $190.51M | $88.95M | $88.61M |
| Operating Cash Flow | -$106.08M | -$122.87M | -$132.26M | -$248.21M | -$162.87M | -$39.23M | -$83.17M | -$38.65M | -$36.82M | -$29.82M |
| Capital Expenditures | $5.95M | $730.0K | $6.15M | $35.57M | $50.70M | $4.93M | $7.39M | $2.30M | $1.73M | $457.0K |
| Shares Outstanding | 115.36M | 113.93M | 98.63M | 97.29M | 95.73M | 87.72M | 75.73M | 64.69M | 52.65M | 41.39M |